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Abstract
Inflammatory bowel diseases (IBD) are chronic inflammatory illnesses marked by unpredictable
disease flares, which occur spontaneously and/or in response to external triggers, especially
personal health behaviors. Behavioral triggers of flare may be responsive to disease self-
management programs. We report on interim findings of a randomized controlled trial of gut-
directed hypnotherapy (HYP, n = 19) versus active attention control (CON, n = 17) for quiescent
ulcerative colitis (UC). To date, 43 participants have enrolled; after 5 discontinuations (1 in HYP)
and 2 exclusions due to excessive missing data, 36 were included in this preliminary analysis. Aim
1 was to determine the feasibility and acceptability of HYP in UC. This was achieved,
demonstrated by a reasonable recruitment rate at our outpatient tertiary care clinic (20%), high
retention rate (88% total), and our representative IBD sample, which is reflected by an equal
distribution of gender, an age range between 21 and 69, recruitment of ethnic minorities (~20%),
and disease duration ranging from 1.5 to 35 years. Aim 2 was to estimate effect sizes on key
clinical outcomes for use in future trials. Effect sizes (group × time at 20 weeks) were small to
medium for IBD self-efficacy (.34), Inflammatory Bowel Disease Questionnaire (IBDQ) total
score (.41), IBDQ bowel (.50), and systemic health (.48). Between-group effects were observed
for the IBDQ bowel health subscale (HYP > CON; p = .05) at 20 weeks and the Short Form 12
Health Survey Version 2 (SF-12v2) physical component (HYP > CON; p < .05) at posttreatment
and 20 weeks. This study supports future clinical trials testing gut-directed HYP as a relapse
prevention tool for IBD.
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Inflammatory bowel diseases (IBD), the most common of which include Crohn’s disease
(CD) and ulcerative colitis (UC), affect as many as 3 million people in North America
(Loftus, 2004; Shanahan & Bernstein, 2009) and cost more than $25,000 per person, per
year in medical expenditures, absenteeism, and lost productivity (Gibson et al., 2008;
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Longobardi & Bernstein, 2007). The course of IBD is chronic and marked by unpredictable
disease flares, which may occur either spontaneously or in response to external triggers
(Hanauer, 2004; Keefer, Keshavarzian, & Mutlu, 2008; Levenstein et al., 2000). Medical
therapy seeks to manage painful and disabling symptoms, increase cancer surveillance, ward
off surgery, and avoid hospitalization whenever possible (Bernstein et al., 2010).
Disease activity, general well-being, quality of life, and health costs in IBD are associated
with personal health behaviors such as: (a) adherence to a medication regimen, including
maintenance medications (Higgins, Rubin, Kaulback, Schoenfield, & Kane, 2009); (b)
management of acute and chronic stress (Keefer et al., 2008; Mawdsley, Macey, Feakins,
Langmead, & Rampton, 2006; Mawdsley & Rampton, 2005); (c) establishment and
maintenance of a collaborative and communicative patient–physician relationship (Moser et
al., 1996; Shoor & Lorig, 2002); (d) quitting smoking (Andrews, Mountifield, Van
Langenberg, Bampton, & Holtmann, 2009); (e) obtaining restorative sleep and managing
fatigue (Keefer, Stepanski, Ranjbaran, Benson, & Keshavarzian, 2006; Ranjbaran et al.,
2007); and (6) maintaining up-to-date knowledge of disease and individual treatment options
(Kiebles, Doerfler, & Keefer, 2010; Moser et al., 1996). We have previously demonstrated
that IBD patients who have difficulty adapting to disease-related demands report more
bowel and systemic symptoms, more pain, less engagement in activities, higher perceived
stress, an emotional representation of illness, and higher health care use (Kiebles et al.,
2010).
Scientific advances may eventually yield safer, more tolerable or nonsurgical curative
therapies for UC. In the meantime, we can optimize current therapy by promoting strong
disease self-management skills. In this communication, we report on interim findings of an
ongoing randomized controlled trial of a disease self-management program featuring gut-
directed hypnosis for quiescent UC. Gut-directed hypnotherapy (HYP) has been an effective
intervention in other gastrointestinal disorders, including irritable bowel syndrome,
noncardiac chest pain, and acid reflux (Francis & Houghton, 1996; Palsson & Whitehead,
2002, 2006). Studies of mechanistic aspects of gut-directed HYP suggest that hypnosis
affects gastrointestinal physiology (gut-transit time, acid secretion) as well as symptom
perception and tolerance (Palsson, Turner, Johnson, Burnett, & Whitehead, 2002). Finally,
this study is an extension of a previously published case series of gut-directed HYP for IBD
that demonstrated improved quality of life (Keefer & Keshavarzian, 2007). Aim 1 is to
determine the feasibility and acceptability of gut-directed HYP in quiescent UC. Aim 2 is to
estimate effect sizes on key clinical outcomes for use in a future, large-scale trial aimed at
IBD self-management more generally. We expected that gut-directed HYP would be a
superior self-management tool for patients with UC when compared to a time and attention




This study is a single-site randomized clinical trial comparing gut-directed HYP versus an
active attention control condition (CON). The Institutional Review Board (IRB) at
Northwestern University approved the study, and all participants to date have signed a
consent form.
Participants
A study coordinator is currently recruiting adult men and women (aged 18–70) with UC,
which has been confirmed by a gastroenterologist via endoscopic standards within the past
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year following a routine well-visit to their gastroenterologist at our outpatient faculty
practice group at Feinberg School of Medicine, Northwestern University. Inclusion criteria
include a flare frequency of ≥ once per year, quiescent disease at time of baseline as
determined by an adapted Mayo score <12 (Higgins, Schwartz, Mapili, & Zimmerman,
2005), and a stable medication regimen for >30 days. Exclusion criteria include active
disease (Mayo score ≥ 12), history of severe or fulminant UC by chart review or physician
report; CD, irritable bowel syndrome, renal or hepatic disease; history of colon resection,
short bowel syndrome, or indeterminate colitis; steroid dependency, smoking cessation ≤30
days prior to baseline; or contra-indications for hypnosis (e.g., cognitive impairment, past
sexual abuse, serious mental illness). Between September 2007 and February 2010, 43
participants were consented and enrolled; 5 participants discontinued participation following
baseline (one of which was in the HYP group), while we excluded 2 from analysis due to
excessive missing data. A total of 36 participants were included in the preliminary analysis.
Upon randomization, we allocated participants to either seven sessions of standardized gut-
directed HYP with one of the two trained hypnotherapists (n = 19) or to a time-equivalent
attention control group (n = 17). See Table 1 for demographic and clinical characteristics by
group.
Treatment Conditions
Both interventions were standardized and conducted on an individual, outpatient basis at a
tertiary gastrointestinal(GI) clinic in an academic medical center. Gut-directed HYP is a
session–session standardized treatment protocol derived and adapted from a previously
validated treatment protocol for IBS (Keefer & Palsson, 2005; Palsson, 2006). Trained
hypnotherapists (LK, JLK) facilitated treatment, which they delivered to participants in
seven weekly, 40-min sessions. Facilitators then instructed participants on continued home-
based practice of the technique on a weekly to biweekly basis during the year following
enrollment. We provided all participants with an audio-file of their hypnotherapist’s voice,
facilitating a self-hypnotic state. Hypnotic suggestions and imagery reflect primary themes
of disease self-management and include maintaining remission, monitoring disease
routinely, early detection of flare activity, managing stress, engendering empowerment,
minimizing extraintestinal symptoms, promoting general health and well-being, and
enhancing self-care.
We developed the CON for this study to control for the effects of clinical attention (Keefer,
Kwiatek, & Kiebles, 2008). A doctoral-level physiologist not formally trained in clinical
psychology or the delivery of psychological treatments (MK) delivered CON. Sessions
include nondirective discussions of the “link between the mind and body in UC” without
reference to relaxation, medication adherence, maintaining remission, self-monitoring, or
other theoretical “active ingredients” in the HYP condition.
Baseline and Process Measures
Baseline sociodemographic and clinical information—Participants were asked to
report demographic and illness-related variables on our standard IBD Center-wide
questionnaire. For this study, we were interested in disease duration, duration of most recent
flare, medication regimen, and history of steroid use, hospitalizations, and smoking.
Participants also reported on the frequency of complementary and alternative medicine
(CAM) use (e.g., Have you ever used any of the following to manage your IBD:
psychotherapy, prayer, meditation, acupuncture, herbal preparations, massage, yoga, other?)
and provided a general medical history.
Inflammatory Bowel Disease Self-Efficacy Scale (IBD-SES)—The IBD-SES
(Keefer, Kiebles, & Taft, 2010) is a 29-item validated disease-specific self-efficacy measure.
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Responses are rated on a 10-point Likert scale ranging from not sure at all to totally sure.
Questions are grouped into four theoretical subscales: managing stress and emotions,
managing medical care, managing symptoms and disease, and maintaining remission. The
overall score of the IBD-SES ranges from 29 to 290, with a higher score suggesting greater
disease-specific self-efficacy.
Perceived Health Competence Scale (PHCS)—The PHCS (Smith, Wallston, &
Smith, 1995) is a domain-specific, validated measure that examines the degree to which an
individual perceives his or her ability to effectively manage his or her own health outcomes
(general health self-efficacy). The PHCS includes eight questions on a 5-point Likert scale
ranging from strongly disagree to strongly agree. Higher scores indicate higher perceived
competence.
Perceived Stress Questionnaire-Recent (PSQ-Recent)—The PSQ-Recent
(Levenstein et al., 1993) is a 30-item validated measure of stress in the past month across
seven factors: harassment, overload, irritability, lack of joy, fatigue, worries, and tension.
Items are rated on a 4-point Likert scale ranging from almost never to usually. Higher scores
suggest greater perceived stress. Researchers have previously reported norms in IBD
(Levenstein et al., 2000).
Rating Form of IBD Patient Concerns (RF-IPC)—The RF-IPC (Drossman, Leserman,
& Li, 1991) is a disease-specific 25-item measure assessing magnitude of specific current
and future worries/concerns related to IBD along a visual analog scale (0–100). Factors
include impact of disease, sexual intimacy, complications of disease, and body stigma. Total
score is the average of all items, with higher scores indicating greater worry and concern.
Drossman and colleagues found higher scores on the RF-IPC to be related to greater disease
severity, female gender, and lower socioeconomic status.
The Medication Adherence Scale (MAS)—The MAS (Morisky, Green, & Levine,
1986) is a widely used (Sewitch et al., 2003) 4-item questionnaire that quantifies adherence
to an IBD medication regimen (Sewitch et al., 2003; Sewitch, Leffondre, & Dobkin, 2004).
The four domains of adherence assessed are (a) forgetting to take medications; (b) being
careless around timing of medications; (c) stopping medication when feeling better; and (d)
stopping medication when feeling worse. A sum score of 0 reflects 100% adherence in the
past month and a sum score of 4 reflects complete lack of adherence.
Outcome Measures
Inflammatory Bowel Disease Questionnaire (IBDQ)—The IBDQ (Irvine, 1999) is a
32-item validated questionnaire designed to assess disease severity and quality of life in
IBD, which yields four subscale scores: bowel health, systemic health, emotional
functioning, and social functioning. Responses are given on a 7-point Likert scale, ranging
from worst function to best function. Lower scores indicate greater disease severity and
lower quality of life.
Short Form 12 Health Survey Version 2 (SF-12v2)—The validated SF-12v2 (Ware,
Kosinski, Turner-Bowker, & Gandek, 2002) includes 12 items from the Short-Form 36
Health Survey (Ware, 1993) and yields physical and mental composite scores as well as
eight subscale values: physical functioning, role-physical, bodily pain, general health,
vitality, social functioning, role-emotional, and mental health. Lower scores correspond with
poorer health-related quality of life.
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For obvious reasons, neither therapists nor participants could be blinded to study condition.
We did take several steps, however, to maximize the integrity of the data and to decrease the
potential for therapist and participant characteristics to threaten the internal validity of this
study. First, a study coordinator collected all of the measures to maintain therapist blinding
to baseline data and follow-up progress, including if/when a flare occurred. Second, we
measured the expectancy and credibility of each condition at pretreatment and posttreatment
(Devilly & Borkovec, 2000), and these measures did not differ, suggesting that participants
were effectively blinded to the hypothesis. Finally, our statistician (ZM), who was otherwise
unfamiliar with the characteristics of the participants, provided block randomization.
Statistical Analysis
We used SPSS 18.0 for Windows (SPSS Inc., Chicago Illinois) to perform statistical
analyses. Data were normally distributed across total scale scores. Data from the RF-IPC
were positively skewed, with most reporting few-to-no IBD-related concerns. We calculated
central tendency and variability, including frequencies, means, standard deviations, and
ranges and used chi-square and Fisher’s exact tests to evaluate differences in proportions of
categorical variables across groups. We performed a 2 × 3 (group × time) mixed design
analysis of variance (ANOVA) with planned contrasts (baseline to posttreatment; baseline to
20 weeks) to determine the effect of treatment on process and outcome measures. We also
calculated effect sizes by dividing the difference in change means at 20 weeks by the
average pooled baseline variance.
Results
Aim 1: Demonstrate Feasibility and Acceptability
Of 212 patients approached, 69 did not return our postclinic follow-up phone call, 30 were
not interested (mainly due to time constraints), and 70 were not eligible. Of the 43 enrolled
(=20% recruitment rate), 5 participants dropped out (only 1 of which completed a single
session of HYP), yielding an 88% rate of retention over a 6-month period with repeated
assessments. All remaining participants assigned to HYP completed all seven sessions of
hypnosis (100% completion). The same was true in the CON, which speaks to the credibility
and acceptability of both interventions. We recommended that participants engage in home-
based practice of the skill five times per week during active treatment. Based on self-
reported adherence to treatment recommendation for at-home practice, only four subjects
were 100% adherent, with a range of 2–100% adherence and an average adherence (54% of
participants) of 2–3 times per week. This rate is consistent with both therapists’ independent
observation.
We had an equal distribution of gender, an age range between 21 and 69 years, and a disease
duration ranging between 1.5 and 35 years. Of our sample, 20% was non-White. Table 1
reports demographic characteristics of participants, demonstrating the feasibility and
acceptability of this intervention to a broad range of patients. Only prior use of CAM, with
53% of HYP and 35% of CON reporting past usage (χ2 = 10.22, p < .05) differed
significantly between the two groups. This difference may be reflective of a randomization
failure, but as this is a pilot study, we have decided to control for this baseline difference
rather than attempt to stratify participants on this variable. There were no additional
differences between HYP and CON at baseline on any categorical or continuous variables.
Aim 2: Estimate Effect Sizes
We calculated the effect size scores based on the difference in change score means divided
by the pooled standard deviation at baseline. This technique considers both groups across
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time illustrating a group × time effect, commensurate with the ANOVA results. We
observed small-to-medium effect sizes (d > .30) for self-efficacy (IBD-SES; d = .34) and for
disease-specific quality of life: IBDQ total score (d = .41), IBDQ bowel health (d = .50), and
systemic health (d = .48).
Between-Group Comparisons on Quality of Life
We conducted a 2 × 3 mixed design ANOVA with follow-up planned t-tests (baseline to
posttreatment; baseline to 20 weeks). There was a statistically significant group-by-time
interaction effect for the IBDQ bowel health subscale (F(1) = 4.1, p < .05) with the hypnosis
condition improving more than the CON at 20 weeks (p = .05). There was also a significant
group-by-time interaction effect for the SF-12v2 physical component summary score (F(1) =
5.3, p < .05) such that the hypnosis condition reported more improvement in physical quality
of life over time at both posttreatment (p = .04) and 20 weeks ( p = .03). See Table 2.
Discussion
Aim 1 of this report on interim findings of our ongoing NIH-funded randomized controlled
trial of a self-management intervention for quiescent UC was to determine the feasibility and
acceptability of gut-directed HYP in UC. Evidence that we have achieved this aim includes
our reasonable recruitment rate at our outpatient tertiary care clinic (20%), a high retention
rate (~88% total, only 1 dropout in HYP), and a range of IBD patients who participated. We
had an equal distribution of gender, an age range between 21 and 69 years, 20% ethnic
diversity, and a disease duration range of 1.5–35 years.
Aim 2 was to estimate effect sizes for key clinical outcomes for use in a future, large-scale
trial aimed at IBD self-management more generally. Effect sizes are a useful way to estimate
clinically relevant changes in health status and, supplemental to standard statistical estimates
of significance, provide “a more complete and clinically relevant picture of health status
change” (Kazis, Anderson, & Meenan, 1989). Cohen’s (1988, 1992) guidelines specify the
following: minimal to no effect 00–.19, small .20–.49, medium .50–.79, and large effects ≥.
80. While Aim 2 was really designed to estimate effect sizes for future trials, we cannot help
but notice that the majority of our effect sizes on key patient outcome variables were greater
than .30 (average effect size across all measures = .31; range .12–.50). We are optimistic
that with a larger sample, the modest effect sizes already seen in self-efficacy and disease-
specific quality of life will warrant future studies aimed at improving disease self-
management in IBD more generally.
Limitations
Our sample was in remission; thus participants were relatively well and their quality of life
was reasonably intact. Despite this, we did see improvements in quality of life and well-
being, suggesting that patients in remission still benefit from disease management skills.
This observation is important because patients are often highly adherent and motivated to
manage their disease during flare but take a more lax approach during remission.
There was a difference between groups on CAM use, which we think may be related to a
randomization failure. Rather than stratify on this variable, we have controlled for prior
CAM use in our analyses. CAM use in IBD is high in general and unlikely to have
significantly influenced our sample (Bernstein, 2004; Burgmann, Rawsthorne, & Bernstein,
2004).
As is usually the case when one reports preliminary data, this study is underpowered (we
would need 23 more subjects to detect true efficacy between groups). However, an estimate
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of effect sizes suggests that efficacy of HYP over CON will be established with an increased
sample size, recruited during the final year of the trial.
We rely solely on self-report measure of outcome in this study. However, future trials aimed
at determining the effects of self-management on disease activity more directly through
standard biomarkers (fecal calprotectin, C-reactive protein, etc.) would further speak to the
impact of such interventions on disease outcome. Finally, the intervention reported here
reflects only a few components of traditional self-management interventions—while these
can be effective, certain patients may require a more comprehensive approach to disease
management.
Summary
Consistent with a social-learning theory view of disease self-management (Bandura, 1977,
2004; Lorig & Holman, 2003), this study demonstrates that when an individual successfully
adopts new health behaviors (e.g., self-hypnosis or stress reduction), they can feel
improvement in the experience of their disease, especially in the areas of self-efficacy and
quality of life. Nursing has an important role in educating and empowering patients with
chronic diseases to use self-management skills to meet the challenges of their disease. This
pilot study suggests that gut-directed HYP may be one aspect of a more comprehensive
disease-management program for IBD.
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Table 1
Baseline Demographic and Clinical Characteristics From the Ulcerative Colitis Relapse Prevention Trial
(UCRPT) for Hypnotherapy (n = 19) and Control (n = 17) Conditions
Variable Hypnotherapy Control p Valuea
Demographics
 Age (mean [SD, range]) 38.6 (11.5, 23–65) 41.5 (13.3, 21–69) NS
 Female gender (frequency [%]) 13 (68%) 8 (47%) NS
 Race: non-Hispanic White (frequency [%]) 15 (79%) 16 (94%) NS
 Marital status: single (frequency [%]) 9 (47%) 6 (35%) NS
 Education: college + (frequency [%]) 16 (84%) 11 (65%) NS
 Use of CAM: sometimes + (frequency [%]) 10 (53%) 6 (35%) <.05
Disease characteristics
 Duration of last flare (weeks; mean [SD, range]) 6.1 (4.9, 1–16) 6.6 (6.0, 0.1–24) NS
 Frequency of hospitalizations (mean [SD, range]) 1.4 (.8, 0–4) 1.4 (1.5, 0–7) NS
 Disease duration (years; mean [SD, range]) 11.0 (8.8, 1.5–35.3) 10.7 (8.6, 1.6–29.5) NS
 Past use of steroids: yes (frequency [%]) 12 (63%) 11 (65%) NS
Process measures
 IBD Self-Efficacy Scale (mean [SD, range]) 219.9 (48.8, 111–288) 219.8 (36.6, 156–290) NS
 Perceived Health Competence Scale (mean [SD, range]) 30.4 (6.0, 16–38) 29.6 (4.5, 22–37) NS
 Perceived Stress Questionnaire (mean [SD, range]) 63.7 (18.5, 31–96) 60.6 (13.5, 41–89) NS
 Overall sleep quality: very good (frequency [%]) 5 (26%) 5 (29%) NS
 Daytime energy: no problem (frequency [%]) 7 (37%) 6 (35%) NS
 Duration of sleep (hr; mean [SD, range]) 6.9 (1.2, 4–9) 7.1 (.9, 5–9) NS
 Rating Form of IBD Patient Concerns (mean [SD, range]) 30.6 (22.6, 4–80) 34.1 (17.7, 1–69) NS
Outcome measures
 IBDQ total score (mean [SD, range]) 190.6 (19.3, 147–220) 192.9 (20.1, 139–216) NS
 IBDQ bowel health (mean [SD, range]) 62.3 (6.3,43–70) 61.1 (6.6,47–70) NS
 IBDQ systemic health (mean [SD, range]) 25.5 (6.6,13–34) 26.2 (5.0,14–32) NS
Short Form Health Survey Version 2 (mean [SD, range])
 Physical component summary 53.9 (4.6, 40–60) 51.1 (7.6, 27–59) NS
 Mental component summary 46.9 (10.2, 27–59) 49.0 (9.0, 31–60) NS
Note: CAM = complementary and alternative medicine; IBD = inflammatory bowel disease; IBDQ = Inflammatory Bowel Disease Questionnaire;
SD = standard deviation.
a
Differences observed between two groups using crosstabulations and chi-square statistic across all categories. No differences were observed
between hypnotherapy and control groups using independent samples t-test (continuous variables).
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